ChengDu ShengNuo BiotecLtd Future Growth
Future criteria checks 5/6
ChengDu ShengNuo BiotecLtd is forecast to grow earnings and revenue by 37.1% and 32.4% per annum respectively while EPS is expected to grow by 37% per annum.
Key information
37.1%
Earnings growth rate
37.0%
EPS growth rate
| Pharmaceuticals earnings growth | 18.6% |
| Revenue growth rate | 32.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 31 Oct 2023 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 800 | 140 | N/A | 83 | 1 |
| 12/31/2024 | 570 | 99 | N/A | 84 | 1 |
| 3/31/2024 | 458 | 73 | -221 | 80 | N/A |
| 12/31/2023 | 435 | 70 | -193 | 85 | N/A |
| 9/30/2023 | 427 | 60 | -188 | 89 | N/A |
| 6/30/2023 | 402 | 66 | -118 | 82 | N/A |
| 3/31/2023 | 396 | 64 | -85 | 83 | N/A |
| 12/31/2022 | 396 | 64 | -40 | 96 | N/A |
| 9/30/2022 | 368 | 57 | -6 | 61 | N/A |
| 6/30/2022 | 360 | 56 | 2 | 72 | N/A |
| 3/31/2022 | 374 | 64 | -2 | 57 | N/A |
| 12/31/2021 | 387 | 61 | -12 | 52 | N/A |
| 9/30/2021 | 387 | 61 | -18 | 48 | N/A |
| 6/30/2021 | 397 | 53 | -8 | 44 | N/A |
| 3/31/2021 | 401 | 62 | 15 | 78 | N/A |
| 12/31/2020 | 379 | 60 | 29 | 81 | N/A |
| 12/31/2019 | 327 | 48 | 0 | 31 | N/A |
| 12/31/2018 | 278 | 30 | 35 | 66 | N/A |
| 12/31/2017 | 194 | 34 | N/A | 58 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688117's forecast earnings growth (37.1% per year) is above the savings rate (2.9%).
Earnings vs Market: 688117's earnings (37.1% per year) are forecast to grow faster than the CN market (23.7% per year).
High Growth Earnings: 688117's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688117's revenue (32.4% per year) is forecast to grow faster than the CN market (14.3% per year).
High Growth Revenue: 688117's revenue (32.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 688117's Return on Equity is forecast to be high in 3 years time